JP2016540826A5 - - Google Patents

Info

Publication number

JP2016540826A5

JP2016540826A5 JP2016552202A JP2016552202A JP2016540826A5 JP 2016540826 A5 JP2016540826 A5 JP 2016540826A5 JP 2016552202 A JP2016552202 A JP 2016552202A JP 2016552202 A JP2016552202 A JP 2016552202A JP 2016540826 A5 JP2016540826 A5 JP 2016540826A5

Authority

JP

Japan

Prior art keywords

antibody

seq

drug conjugate

variable region

chain variable

Prior art date

2014-10-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000611 antibody drug conjugate Substances 0.000 claims description 88
• 229940049595 antibody-drug conjugate Drugs 0.000 claims description 88
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
• 239000000203 mixture Substances 0.000 claims description 26
• 239000003814 drug Substances 0.000 claims description 24
• 229940079593 drug Drugs 0.000 claims description 22
• 238000000034 method Methods 0.000 claims description 18
• 230000001613 neoplastic effect Effects 0.000 claims description 15
• 206010066476 Haematological malignancy Diseases 0.000 claims description 8
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 8
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
• 230000003463 hyperproliferative effect Effects 0.000 claims description 8
• 210000005102 tumor initiating cell Anatomy 0.000 claims description 8
• 210000004881 tumor cell Anatomy 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 5
• FNHIEZKOCYDCOH-UHFFFAOYSA-N 4-(4-acetylphenoxy)butanoic acid Chemical compound CC(=O)C1=CC=C(OCCCC(O)=O)C=C1 FNHIEZKOCYDCOH-UHFFFAOYSA-N 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 206010009944 Colon cancer Diseases 0.000 claims description 4
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
• 102100033942 Ephrin-A4 Human genes 0.000 claims description 4
• 101000925259 Homo sapiens Ephrin-A4 Proteins 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
• 239000000427 antigen Substances 0.000 claims description 4
• 102000036639 antigens Human genes 0.000 claims description 4
• 108091007433 antigens Proteins 0.000 claims description 4
• 239000012634 fragment Substances 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 201000007270 liver cancer Diseases 0.000 claims description 4
• 208000014018 liver neoplasm Diseases 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 3
• 229930195731 calicheamicin Natural products 0.000 claims description 3
• 239000000562 conjugate Substances 0.000 claims description 3
• 230000001268 conjugating effect Effects 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims description 2
• YNMOQZAXBPAHQF-UHFFFAOYSA-N 2-(4-acetylphenoxy)butanoic acid Chemical compound CCC(C(O)=O)OC1=CC=C(C(C)=O)C=C1 YNMOQZAXBPAHQF-UHFFFAOYSA-N 0.000 claims 1
• 101100171806 Homo sapiens EFNA4 gene Proteins 0.000 description 1
• 125000003047 N-acetyl group Chemical group 0.000 description 1
• WPDOZYZAJKUVRZ-NRYSMURASA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5Z,9R)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-methyloxan-3-yl]amino]oxy-4-hydroxy-2-methyloxan-3-yl] 4-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-5-iodo-2,3-dimethoxy-6-methylbenzenecarbothioate Chemical compound CCN([C@H]1CO[C@H](C[C@@H]1OC)O[C@@H]1[C@@H](O)[C@H](NO[C@H]2C[C@H](O)[C@H](SC(=O)c3c(C)c(I)c(O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)[C@H]4O)c(OC)c3OC)[C@@H](C)O2)[C@@H](C)O[C@H]1O[C@H]1C#C\C=C/C#C[C@]2(O)CC(=O)C(NC(=O)OC)=C1C2=CCSSSC)C(C)=O WPDOZYZAJKUVRZ-NRYSMURASA-N 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1